Condition: Hemophilia A · Sponsor: Emory University
The purpose of the aPCC-emicizumab safety study is to investigate the hemostatic efficacy as measured by thrombin generation, of a low personalized dose of aPCC (FEIBA) in children and adults with hemophilia A and inhibitors on emicizumab prophylaxis.
This description comes directly from the study's public registry record.
Robert Sidonio, MD · 404-785-1637 · robert.sidonio.jr@emory.edu
Always discuss trial participation with your own doctor first.
| Children's Healthcare of Atlanta | Atlanta, Georgia, United States | Recruiting |
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04563520